DNA vaccine was regarded as one of the most promising approaches for future vaccine developmentin light of its capability of overcoming the disadvantages in conventional vaccines (such ascapability of inducing both humoral and cellular immunity) and of its stability as well as simplicityof production.

To evaluate the biosafety and the actual immune effect of the Rabies Virus Glycoprotein and Nucleoprotein “bivalent”DNA vaccines-pVGN, the following trials have been fulfilled.

Immunization with DNA vaccine affords an opportunity to establish a new preventive procedure against CVB3 infections.

Synthesis Poly(LacNAc/Gln - co - Gln) as DNA Vaccine Adjuvant;

The prime-boost strategy with mucosal DNA vaccine and killed oil-emulsified vaccine against H9 subtype of avian influenza virus;

Immunotherapeutic effect of Ag85A DNA vaccine and Ag85B DNA vaccine on bladder tumor in rats;

Immune mechanism of DNA vaccines and progress on Newcastle disease virus (NDV);

Research advances in genetic adjuvant for DNA vaccines and its application in fish vaccines;

Study of immune responses induced by human papillomavirus type 18 L1-E6 and L1-E7 chimeric gene DNA vaccines in mice;

Objective To elucidate the effect of DNA immunization against neurite growth inhibitors on the neurological improvement following local cerebral ischemia.

Effect of Ag85A DNA vaccine on FasL mRNA expression in intestinal intraepithelial lymphocytes;